< Back

Galapagos to deliver four presentations at EULAR 2011

24 May 2011 at 16:01 CET

Mechelen, Belgium; 24 May 2011- Galapagos NV (Euronext: GLPG) announced that four abstracts have been selected for presentation at the Annual European Congress of Rheumatology (EULAR) taking place 25-28 May 2011 at the ExCel Congress Centre in London.  Presentations will include pre-clinical and early clinical findings on two programs: GLPG0634, a selective JAK1 inhibitor being developed for rheumatoid arthritis, and GLPG0259, a small molecule inhibitor of the kinase MAPKAPK5. 


GLPG0634/JAK1 inhibitor:


GLPG0259/MAPKAPK5 inhibitor:



The full abstracts can be accessed through the EULAR conference website or www.eular.org.  After the presentation and posters are presented they will be available in PDF format on Galapagos' website: www.glpg.com.



For more information:


Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240



Title Download